Standardized Pathology Report for Colorectal Cancer, 2nd Edition

The first edition of the ‘Standardized Pathology Report for Colorectal Cancer,’ which was developed by the Gastrointestinal Pathology Study Group (GIP) of the Korean Society of Pathologists, was published 13 years ago. Meanwhile, there have been many changes in the pathologic diagnosis of colorectal cancer (CRC), pathologic findings included in the pathology report, and immunohistochemical and molecular pathology required for the diagnosis and treatment of colorectal cancer. In order to reflect these changes, we (GIP) decided to make the second edition of the report. The purpose of this standardized pathology report is to provide a practical protocol for Korean pathologists, which could help diagnose and treat CRC patients. This report consists of “standard data elements” and “conditional data elements.” Basic pathologic findings and parts necessary for prognostication of CRC patients are classified as “standard data elements,” while other prognostic factors and factors related to adjuvant therapy are classified as “conditional data elements” so that each institution could select the contents according to the characteristics of the institution. The Korean version is also provided separately so that Korean pathologists can easily understand and use this report. We hope that this report will be helpful in the daily practice of CRC diagnosis.

[1]  D. Sargent,et al.  Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.

[2]  김우호,et al.  A Standardized Pathology Report for Colorectal Cancer , 2006 .

[3]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[4]  M. Pollheimer,et al.  Intramural and extramural vascular invasion in colorectal cancer , 2012, Cancer.

[5]  G Milano,et al.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[7]  Shuji Ogino,et al.  Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[8]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[9]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[10]  M. Pino,et al.  Microsatellite instability in the management of colorectal cancer , 2011, Expert review of gastroenterology & hepatology.

[11]  L. Reggiani Bonetti,et al.  Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectal mucinous adenocarcinoma. , 2015, Human pathology.

[12]  P. Lønning,et al.  Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases , 2016, International journal of cancer.

[13]  I. Nagtegaal,et al.  Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions , 2013, Endoscopy.

[14]  R. Riddell,et al.  Tumor budding in colorectal carcinoma: time to take notice , 2012, Modern Pathology.

[15]  J. Park,et al.  What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[16]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[17]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[18]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[19]  J. Skibber,et al.  Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative Chemoradiation , 2010, Annals of surgery.

[20]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[21]  Seung-Yong Jeong,et al.  Indications for Subsequent Surgery After Endoscopic Resection of Submucosally Invasive Colorectal Carcinomas: A Prospective Cohort Study , 2009, Diseases of the colon and rectum.

[22]  D. Berger,et al.  Perineural invasion in cancer , 2009, Cancer.

[23]  M. Schwartz,et al.  Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis , 2007, Modern Pathology.

[24]  H. McLeod,et al.  Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. , 2002, European journal of cancer.

[25]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[26]  D. Berger,et al.  Perineural invasion is an independent predictor of outcome in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[28]  B. Leggett,et al.  Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry , 2017, Modern Pathology.

[29]  J. H. Kim,et al.  Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[30]  B. Molnár,et al.  Serrated pathway: alternative route to colorectal cancer. , 2013, World journal of gastroenterology.

[31]  C. Gutschow,et al.  Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer , 2012, International Journal of Colorectal Disease.

[32]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Liakka,et al.  Morphology and microsatellite instability in sporadic serrated and non‐serrated colorectal cancer , 2005, The Journal of pathology.

[34]  Y. Nakanishi,et al.  Clinicopathological significance of microscopic abscess formation at the invasive margin of advanced low rectal cancer , 2007, The British journal of surgery.

[35]  Joanna A Gibson,et al.  Pathology of premalignant colorectal neoplasia , 2016, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[36]  A. Mattia,et al.  A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome , 2017, Modern Pathology.

[37]  D. Treanor,et al.  Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancer , 2005, Histopathology.

[38]  J. Jass,et al.  A NEW PROGNOSTIC CLASSIFICATION OF RECTAL CANCER , 1987, The Lancet.

[39]  D. Sargent,et al.  Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials , 2017, JAMA oncology.

[40]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[41]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Wendy Frankel,et al.  Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. , 2009, Archives of pathology & laboratory medicine.

[44]  A. Krasinskas EGFR Signaling in Colorectal Carcinoma , 2011, Pathology research international.

[45]  J. O’Sullivan,et al.  Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer , 2009, The American journal of surgical pathology.

[46]  H. Lee,et al.  Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells , 2013, Modern Pathology.

[47]  O. Dworak,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.

[48]  X. Puig,et al.  Clinicopathological and molecular characterization of colorectal micropapillary carcinoma , 2011, Modern Pathology.

[49]  E. Dogliotti,et al.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.

[50]  A. Zaitoun,et al.  Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. , 2011, European journal of cancer.

[51]  N. Shepherd,et al.  Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) ‐ Pathology Standards and Datasets , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[52]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Boland,et al.  An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers , 2010, PloS one.

[54]  I. Mihaylova,et al.  Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer-Preliminary results. , 2011, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[55]  N. Shepherd,et al.  UK guidance for the pathological reporting of serrated lesions of the colorectum , 2015, Journal of Clinical Pathology.

[56]  M. Mäkinen,et al.  Colorectal serrated adenocarcinoma , 2007, Histopathology.

[57]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. , 2017, Archives of pathology & laboratory medicine.

[59]  R. Haggitt,et al.  Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. , 1985, Gastroenterology.

[60]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[61]  J. Galon,et al.  Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. , 2016, International immunology.

[62]  Claudia Maggi,et al.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.

[63]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Serra,et al.  Traditional serrated adenomas (TSAs) admixed with other serrated (so-called precursor) polyps and conventional adenomas: a frequent occurrence , 2015, Journal of Clinical Pathology.

[65]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[66]  C. Belda-Iniesta,et al.  EGFR and colon cancer: a clinical view , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[67]  M. Kurrer,et al.  Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer , 2012, Modern Pathology.

[68]  Clinicopathological significance of Ki67 expression in colorectal cancer , 2020, Medicine.

[69]  P. Laird,et al.  Association between molecular subtypes of colorectal cancer and patient survival. , 2015, Gastroenterology.

[70]  I. Nagtegaal,et al.  Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour , 2004, The Journal of pathology.

[71]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  F. Offner,et al.  Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study , 2015, Virchows Archiv.

[73]  R. Nozaki,et al.  Management of early invasive colorectal cancer , 1995, Diseases of the colon and rectum.

[74]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[75]  K. Song,et al.  A Standardized Pathology Report for Gastric Cancer , 2005 .

[76]  Colin C Pritchard,et al.  Colorectal cancer molecular biology moves into clinical practice , 2010, Gut.

[77]  H. Nassar Carcinomas with Micropapillary Morphology: Clinical Significance and Current Concepts , 2004, Advances in anatomic pathology.

[78]  K. Jakubowska,et al.  Invasive micropapillary component and its clinico-histopathological significance in patients with colorectal cancer. , 2016, Oncology letters.

[79]  E. Sabo,et al.  Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[81]  Zongguang Zhou,et al.  K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. , 2015, Hepato-gastroenterology.

[82]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[83]  W. Samowitz Evaluation of colorectal cancers for Lynch syndrome: practical molecular diagnostics for surgical pathologists , 2015, Modern Pathology.

[84]  Toshihide Kumamoto,et al.  Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study , 2004, Journal of Gastroenterology.

[85]  R. Riddell,et al.  Cytokeratin‐based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience , 2017, The journal of pathology. Clinical research.

[86]  D. Sargent,et al.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.

[87]  A. Rogers,et al.  Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy , 2014, Modern Pathology.

[88]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[89]  B. Memon,et al.  Outcome of acutely perforated colorectal cancers: experience of a single district general hospital. , 2006, Surgical oncology.

[90]  Iris D. Nagtegaal,et al.  The Importance of the Pathologist’s Role in Assessment of the Quality of the Mesorectum , 2012, Current Colorectal Cancer Reports.

[91]  E. Friedman,et al.  Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  D. McMillan,et al.  The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.

[93]  R. Yantiss,et al.  Histologic Features and Cytologic Techniques That Aid Pathologic Stage Assessment of Colonic Adenocarcinoma , 2013, The American journal of surgical pathology.

[94]  M. Kojima,et al.  Intramucosal colorectal carcinoma with invasion of the lamina propria: a study by the Japanese Society for Cancer of the Colon and Rectum. , 2017, Human pathology.

[95]  C. Eng,et al.  The current landscape of locally advanced rectal cancer , 2011, Nature Reviews Clinical Oncology.

[96]  April Fritz,et al.  International Classification of Diseases for Oncology: ICD-0. , 2000 .

[97]  M. Lai,et al.  Micropapillary Component in Colorectal Carcinoma is Associated With Lymph Node Metastasis in T1 and T2 Stages and Decreased Survival Time in TNM Stages I and II , 2009, The American journal of surgical pathology.

[98]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[99]  E. Rullier,et al.  Prise en charge des cancers du rectum localement avancés : quel rôle pour le pathologiste en 2011 ? , 2011 .

[100]  W. Samowitz,et al.  Microsatellite instability and colorectal cancer. , 2011, Archives of pathology & laboratory medicine.

[101]  Charles J. Kahi,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.